Todd C Davis
CIK 1392029 · Chief Executive Officer · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$102.87M
Companies
6
Total Filings
80
Lifetime Open-Market Net
-$4.55M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LGND | Chief Executive Officer | 199,513 | $296.28 | $59.11M | -$5.35M | 50 | 2026-07-06 |
| PTHS | Director | 1,575,834 | $27.77 | $43.76M | $1000.0K | 3 | 2026-06-15 |
| PVLA | Director | — | $142.84 | — | $0 | 3 | 2026-06-12 |
| Pelthos Therapeutics Inc. (CHRO) Delisted | Director | 2,917 | $13.50 | $39.4K | $0 | 3 | 2024-11-15 |
| Vaxart, Inc. (VXRT) Delisted | Director | 125,905 | $0.32 | $40.3K | -$196.5K | 7 | 2022-08-08 |
| ARTES MEDICAL INC (ARTE) Delisted | Director | — | $10.73 | — | $0 | 3 | 2008-02-15 |
Recent Filings · Page 2 of 8
80 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-11 | PVLA | Grant (A) | — | $0 | EDGAR |
| 2025-05-13 | LGND | Buy (P) | +9,510 | $1.00M | EDGAR |
| 2025-03-06 | LGND | Grant (A) | +21,382 | $0 | EDGAR |
| 2025-02-19 | LGND | Mixed | +7,332 | -$1.61M | EDGAR |
| 2024-12-17 | PVLA | Grant (A) | — | $0 | EDGAR |
| 2024-11-15 | Pelthos Therapeutics Inc. (CHRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-09 | LGND | Buy (P) | +2,500 | $243.5K | EDGAR |
| 2024-07-02 | LGND | Other (J) | +350 | $21.2K | EDGAR |
| 2024-06-18 | Pelthos Therapeutics Inc. (CHRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-27 | LGND | Exer (M) | +16,015 | $919.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.